Vnitr Lek 2009, 55(9):788-791

Diabetes and vascular diabetic disease

J. Murín*, M. Yaghy
I. interná klinika Lekárskej fakulty UK Bratislava, Slovenská republika, prednostka doc. MUDr. Soňa Kiňová, Ph.D.

The prevalence of type 2 diabetes mellitus is growing. Vascular disease is here the main cause of morbidity and mortality, and accelerated atherosclerosis is responsible for about 80% of mortality and for about 75% of hospitalizations. In diabetics there is 2-4times greater risk of ischemic heart disease in comparison to non-diabetics, and this risk is even greater in diabetic-females. Authors put greater attention to pathophysiology of diabetic vascular disease (inflammation and adipose tissue, metabolic and other - AGEs, ADMA - abnormalities, their contribution to endothelial dysfunction). The main concern is devoted to the treatment possibilities of diabetic vascular disease.

Keywords: type 2 diabetes mellitus; vascular diabetic disease; ischemic heart disease; inflammation and adipose tissue; endothelial dysfunction

Received: June 15, 2009; Published: September 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Murín J, Yaghy M. Diabetes and vascular diabetic disease. Vnitr Lek. 2009;55(9):788-791.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology and management. JAMA 2002; 287: 2570-2581. Go to original source... Go to PubMed...
    2. Mokáň M, Galajda P, Prídavková D et al. Prevalence of diabetes mellitus and metabolic syndrome in Slovakia. Diabete Res Clin Pract 2008; 81: 238-242. Go to original source... Go to PubMed...
    3. Lüscher TF, Creager MA, Beckman JA et al. Diabetes and vascular disease - pathophysiology, clinical consequences and medical therapy, part II. Circulation 2003; 108: 1655-1661. Go to original source... Go to PubMed...
    4. MRFIT Research group: Mortality after 10 and half years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990; 82: 1616-1628. Go to original source... Go to PubMed...
    5. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281: 1291-1297. Go to original source... Go to PubMed...
    6. Haffner SM, Lehto S, Rönnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-334. Go to original source... Go to PubMed...
    7. Shindler DM, Palmeri ST, Antonelli TA et al. Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol 2000; 36 (3 Suppl A): 1097-1103. Go to original source... Go to PubMed...
    8. Berg AH, Scherer PE. Adipose tissue, inflammation and cardiovascular disease. Circ Res 2005; 96: 939-949. Go to original source... Go to PubMed...
    9. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116: 1793-1801. Go to original source... Go to PubMed...
    10. Creager MA, Lüscher TF, Cosentino F et al. Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy. Part I. Circulation 2003; 108: 1527-1532. Go to original source... Go to PubMed...
    11. Lin KY, Ito A, Asagami T et al. Impaired NO synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine dimethylaminohydrolase. Circulation 2002; 106: 987-992. Go to original source... Go to PubMed...
    12. Goldin A, Beckman JA, Schmidt AM et al. Advanced glycation end-products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605. Go to original source... Go to PubMed...
    13. Uemura S, Matsushita H, Li W et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001; 88: 1291-1298. Go to original source... Go to PubMed...
    14. Sudic D, Razmara M, Forslund M et al. High glucose levels enhance platelet activation: involvement of multiple mechanisms. Br J Haematol 2006; 133: 315-322. Go to original source... Go to PubMed...
    15. Eckel RH, Wassef M, Chait A et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation 2002; 105: e138-e143. Go to original source... Go to PubMed...
    16. Ratner R, Goldberg R, Haffner S et al. Impact of intensive life style and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care 2005; 28: 888-894. Go to original source... Go to PubMed...
    17. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2. diabetes. Lancet 1998; 352: 837-853. Go to original source...
    18. Nathan DM, Lachin J, Cleary PA et al. Intensive diabetes therapy and carotid intimo-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-2303. Go to original source... Go to PubMed...
    19. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653. Go to original source... Go to PubMed...
    20. Chiasson JL, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA 2003; 290: 486-494. Go to original source... Go to PubMed...
    21. Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipids in type 2 diabetes mellitus and metabolic syndrome. Am J Cardiovasc Drugs 2005; 5: 379-387. Go to original source... Go to PubMed...
    22. Beckman JA, Creager, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology and management. JAMA 2002; 287: 2570-2581. Go to original source... Go to PubMed...
    23. Collins R, Armitage J, Parish S et al. MRC/BHF Heart Protection Study of Cholesterol-lowering with simvastatin in 5.963 patients with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016. Go to original source...
    24. Sever PS, Poulter NR, Dahlöf B et al. Reduction in cardiovascular events with atorvastatin in 2.532 patients with type 2 diabetes: Anglo-Scandinavian Cardiovascular Outcomes Trial-lipid lowering arm. Diabetes Care 2005; 28: 1151-1157. Go to original source... Go to PubMed...
    25. Rubins HB, Robins SJ, Collins DJ et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of HDL-Ch. Veterans Affairs HDL-Ch. Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418. Go to original source... Go to PubMed...
    26. Lefebvre P, Chinetti G, Fruchart JC et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006; 116: 571-580. Go to original source... Go to PubMed...
    27. Mehler PS, Coll JR, Estacio R et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003; 107: 753-756. Go to original source... Go to PubMed...
    28. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents and setting priorities in diabetes care. Ann Intern Med 2003; 138: 593-602. Go to original source... Go to PubMed...
    29. Deinum J, Chaturvedi N. The renin-angiotensin system and vascular disease in diabetes. Semin Vasc Med 2002; 2: 149-156. Go to original source... Go to PubMed...
    30. HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-259. Go to original source...
    31. Lindholm LH, Ibsen H, Dahlöf B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). A randomised trial against atenolol. Lancet 2002; 359: 1004-1010. Go to original source... Go to PubMed...
    32. Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.